# PEG (Polyethylene Glycol)Versus Lactulose For Treatment Of Overt Hepatic Encephalopathy

> **NCT03100513** · PHASE4 · UNKNOWN · sponsor: **Sherief Abd-Elsalam** · enrollment: 100 (estimated)

## Conditions studied

- Hepatic Encephalopathy

## Interventions

- **DRUG:** Lactulose
- **DRUG:** Polyethylene Glycol

## Key facts

- **NCT ID:** NCT03100513
- **Lead sponsor:** Sherief Abd-Elsalam
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-03-11
- **Primary completion:** 2019-10
- **Final completion:** 2019-12
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2017-04-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03100513

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03100513, "PEG (Polyethylene Glycol)Versus Lactulose For Treatment Of Overt Hepatic Encephalopathy". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03100513. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*